This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by COLWELL, C. W.
Right arrow Articles by HARDWICK, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by COLWELL, C. W.
Right arrow Articles by HARDWICK, M. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Technorati  
What's this?
The Journal of Bone and Joint Surgery 81:932-40 (1999)
© 1999 The Journal of Bone and Joint Surgery, Inc.

Comparison of Enoxaparin and Warfarin for the Prevention of Venous Thromboembolic Disease After Total Hip Arthroplasty. Evaluation During Hospitalization and Three Months After Discharge*

CLIFFORD W. COLWELL, JR. M.D.{ddagger}, LA JOLLA, DENNIS K. COLLIS, M.D.{ddagger}, EUGENE, OREGON, ROLF PAULSON, M.D.§, GRAND FORKS, NORTH DAKOTA, JOHN W. McCUTCHEN, M.D.#, WINTER PARK, FLORIDA, GREGORY T. BIGLER, M.D.**, LAS VEGAS, NEVADA, SUSAN LUTZ, R.N.{dagger}{dagger}, CHALFONT, PENNSYLVANIA and MARY E. HARDWICK, M.S.N.{ddagger}, LA JOLLA, CALIFORNIA

Background: Venous thromboembolic disease in the form of deep venous thrombosis and pulmonary embolism is a major risk after a total hip arthroplasty. Enoxaparin, a low-molecular-weight heparin, has been shown to reduce the prevalence of deep venous thrombosis after total hip arthroplasty. Warfarin, an orally administered anticoagulant, has been used historically to reduce the risk of deep venous thrombosis after total hip arthroplasty. Methods: We compared enoxaparin and adjusted-dose warfarin with respect to their safety and their efficacy in the prevention of clinically important venous thromboembolic disease, defined as distal or proximal deep venous thrombosis or pulmonary embolism, or both, during hospitalization after total hip arthroplasty. We also evaluated the prevalence of complications and mortality from venous thromboembolic disease within three months after discharge. Results: Three thousand and eleven patients at 156 centers were randomly assigned to prophylactic treatment with injection of enoxaparin or oral administration of adjusted-dose warfarin during hospitalization. During the study, fifty-five (3.6 percent) of the 1516 patients who were managed with enoxaparin and fifty-six (3.7 percent) of the 1495 patients who were managed with warfarin had venous thromboembolic disease. Twenty-one patients (0.7 percent), which included four (0.3 percent) of those managed with enoxaparin and seventeen (1.1 percent) of those managed with warfarin (p = 0.0083), had venous thromboembolic disease during hospitalization. After discharge from the hospital, venous thromboembolic disease developed in ninety patients (3.0 percent): fifty-one (3.4 percent) of those managed with enoxaparin and thirty-nine (2.6 percent) of those managed with warfarin. One patient who had been managed with enoxaparin died because of a pulmonary embolism, which was confirmed at autopsy. Three additional patients (one who had been managed with enoxaparin and two who had been managed with warfarin) died, and the deaths were attributed to venous thromboembolic disease; however, no autopsies were performed. Twenty-six patients (0.9 percent) (eighteen managed with enoxaparin and eight managed with warfarin) had clinically important bleeding. Conclusions: Inpatient programs providing treatment with either enoxaparin (thirty milligrams every twelve hours) or adjusted-dose warfarin for a mean of 7.3 days afforded protection against venous thromboembolic disease, with overall rates of morbidity and mortality of 3.7 and 0.6 percent, respectively, and a very low rate of major bleeding complications (0.9 percent) for three months after total hip arthroplasty. During hospitalization, the patients managed with enoxaparin had a lower rate of venous thromboembolic disease than those managed with adjusted-dose warfarin (p = 0.0083). This benefit was lost after the medication was discontinued, with no difference in the prevalences of venous thromboembolic disease between the two groups at three months after discharge from the hospital.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
A. F Shorr, E. A Nutescu, E. Farrelly, R. Horblyuk, L. E Happe, and M. Franklin
Postdischarge Oral Versus Injectable Anticoagulation Following Major Orthopedic Surgery
Ann. Pharmacother., September 1, 2008; 42(9): 1222 - 1228.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell
Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 381S - 453S.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
L. D. Dorr, V. Gendelman, A. V. Maheshwari, M. Boutary, Z. Wan, and W. T. Long
Multimodal Thromboprophylaxis for Total Hip and Knee Arthroplasty Based on Risk Assessment
J. Bone Joint Surg. Am., December 1, 2007; 89(12): 2648 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. Edelsberg, M. Hagiwara, C. Taneja, and G. Oster
Risk of venous thromboembolism among hospitalized medically ill patients.
Am. J. Health Syst. Pharm., October 15, 2006; 63(20 Suppl 6): S16 - S22.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
E. A Nutescu, A. K Wittkowsky, P. P Dobesh, D. W Hawkins, and W. E Dager
Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach
Ann. Pharmacother., September 1, 2006; 40(9): 1558 - 1570.
[Abstract] [Full Text] [PDF]

Home page
 Canadian J. AnesthesiaHome page
S. Motte, C. M. Samama, J. Guay, J. Barre, J.-Y. Borg, and N. Rosencher
Prevention of postoperative venous thromboembolism. Risk assessment and methods of prophylaxis: [La prevention de la thromboembolie veineuse postoperatoire. Evaluation du risque et methodes de prophylaxie]
Can J Anesth, June 1, 2006; 53(6_suppl): S68 - S79.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. L. Schiff, S. R. Kahn, I. Shrier, C. Strulovitch, W. Hammouda, E. Cohen, and D. Zukor
Identifying Orthopedic Patients at High Risk for Venous Thromboembolism Despite Thromboprophylaxis
Chest, November 1, 2005; 128(5): 3364 - 3371.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
J. R. Lieberman and W. K. Hsu
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
J. Bone Joint Surg. Am., September 1, 2005; 87(9): 2097 - 2112.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. J Enyart and R. J Jones
Low-Dose Warfarin for Prevention of Symptomatic Thromboembolism After Orthopedic Surgery
Ann. Pharmacother., June 1, 2005; 39(6): 1002 - 1007.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
P. K. Chan, I. J Brenkel, and J. Aderinto
The outcome of total hip arthroplasty in diabetes mellitus
The British Journal of Diabetes & Vascular Disease, May 1, 2005; 5(3): 146 - 149.
[Abstract] [PDF]

Home page
 Anesth. Analg.Home page
J. C. Rowlingson and P. B. Hanson
Neuraxial Anesthesia and Low-Molecular-Weight Heparin Prophylaxis in Major Orthopedic Surgery in the Wake of the Latest American Society of Regional Anesthesia Guidelines
Anesth. Analg., May 1, 2005; 100(5): 1482 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
G. Agnelli
Prevention of Venous Thromboembolism in Surgical Patients
Circulation, December 14, 2004; 110(24_suppl_1): IV-4 - IV-12.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
M. McGuire and P. P. Dobesh
Therapeutic Update on the Prevention and Treatment of Venous Thromboembolism
Journal of Pharmacy Practice, October 1, 2004; 17(5): 289 - 307.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
S. A. Hilty
Update in Perioperative Medicine
Ann Intern Med, September 21, 2004; 141(6): 486 - 486.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
G. W. Smetana, S. L. Cohn, and V. A. Lawrence
Update in Perioperative Medicine
Ann Intern Med, September 21, 2004; 141(6): 486 - 487.
[Full Text] [PDF]

Home page
 JBJSHome page
J. Parvizi, M. H. Ereth, and D. G. Lewallen
Thirty-Day Mortality Following Hip Arthroplasty for Acute Fracture
J. Bone Joint Surg. Am., September 1, 2004; 86(9): 1983 - 1988.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
W. H. Geerts, G. F. Pineo, J. A. Heit, D. Bergqvist, M. R. Lassen, C. W. Colwell, and J. G. Ray
Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 338S - 400S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. Mosen, C. G. Elliott, M. J. Egger, M. Mundorff, J. Hopkins, R. Patterson, and R. M. Gardner
The Effect of a Computerized Reminder System on the Prevention of Postoperative Venous Thromboembolism
Chest, May 1, 2004; 125(5): 1635 - 1641.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
R. Radl, N. Kastner, C. Aigner, H. Portugaller, H. Schreyer, and R. Windhager
Venous Thrombosis After Hallux Valgus Surgery
J. Bone Joint Surg. Am., July 3, 2003; 85(7): 1204 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
E. A Nutescu, R. K Lewis, J. M Finley, and G. T Schumock
Hospital Guidelines for Use of Low-Molecular-Weight Heparins
Ann. Pharmacother., July 1, 2003; 37(7): 1072 - 1081.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. O'Donnell, L.-A. Linkins, C. Kearon, J. Julian, and J. Hirsh
Reduction of Out-of-Hospital Symptomatic Venous Thromboembolism by Extended Thromboprophylaxis With Low-Molecular-Weight Heparin Following Elective Hip Arthroplasty: A Systematic Review
Arch Intern Med, June 9, 2003; 163(11): 1362 - 1366.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
T. M. Hyers
Management of Venous Thromboembolism: Past, Present, and Future
Arch Intern Med, April 14, 2003; 163(7): 759 - 768.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. B Deitelzweig, G. J Vanscoy, C. S Niccolai, and T. L Rihn
Venous Thromboembolism Prevention with LMWHs in Medical and Orthopedic Surgery Patients
Ann. Pharmacother., March 1, 2003; 37(3): 402 - 411.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
C. B. Phillips, J. A. Barrett, E. Losina, N. N. Mahomed, E. A. Lingard, E. Guadagnoli, J. A. Baron, W. H. Harris, R. Poss, and J. N. Katz
Incidence Rates of Dislocation, Pulmonary Embolism, and Deep Infection During the First Six Months After Elective Total Hip Replacement
J. Bone Joint Surg. Am., January 17, 2003; 85(1): 20 - 26.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
D. R. Anderson, S. J.-A. Wilson, J. Blundell, D. Petrie, R. Leighton, W. Stanish, D. Alexander, K. S. Robinson, E. Burton, and M. Gross
Comparison of a Nomogramand Physician-Adjusted Dosageof Warfarin for Prophylaxis Against Deep-Vein Thrombosis After Arthroplasty
J. Bone Joint Surg. Am., November 12, 2002; 84(11): 1992 - 1997.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
C. M. Samama, M. Vray, J. Barre, J.-N. Fiessinger, N. Rosencher, T. Lecompte, G. Potron, J. Basile, R. Hull, D. Desmichels, et al.
Extended Venous Thromboembolism Prophylaxis After Total Hip Replacement: A Comparison of Low-Molecular-Weight Heparin With Oral Anticoagulant
Arch Intern Med, October 28, 2002; 162(19): 2191 - 2196.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
P. Prandoni, O. Bruchi, P. Sabbion, C. Tanduo, A. Scudeller, C. Sardella, G. Errigo, F. Pietrobelli, G. Maso, and A. Girolami
Prolonged Thromboprophylaxis With Oral Anticoagulants After Total Hip Arthroplasty: A Prospective Controlled Randomized Study
Arch Intern Med, September 23, 2002; 162(17): 1966 - 1971.
[Abstract] [Full Text] [PDF]

Home page
 J Am Acad Orthop SurgHome page
P. G. Whang and J. R. Lieberman
Low-Molecular-Weight Heparin
J. Am. Acad. Ortho. Surg., September 1, 2002; 10(5): 299 - 302.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
J. D. Douketis, J. W. Eikelboom, D. J. Quinlan, A. R. Willan, and M. A. Crowther
Short-Duration Prophylaxis Against Venous Thromboembolism After Total Hip or Knee Replacement: A Meta-analysis of Prospective Studies Investigating Symptomatic Outcomes
Arch Intern Med, July 8, 2002; 162(13): 1465 - 1471.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
T. P. Sculco, C. W. Colwell Jr., V. D. Pellegrini Jr., G. H. Westrich, and F. Bottner
Prophylaxis Against Venous Thromboembolic Disease in Patients Having a Total Hip or Knee Arthroplasty
J. Bone Joint Surg. Am., March 1, 2002; 84(3): 466 - 477.
[Full Text]

Home page
 JBJSHome page
R. P. Pitto, H. Hamer, R. Fabiani, M. Radespiel-Troeger, and M. Koessler
Prophylaxis Against Fat and Bone-Marrow Embolism During Total Hip Arthroplasty Reduces the Incidence of Postoperative Deep-Vein Thrombosis : A Controlled, Randomized Clinical Trial
J. Bone Joint Surg. Am., January 1, 2002; 84(1): 39 - 48.
[Abstract] [Full Text]

Home page
 ANN INTERN MEDHome page
R. D. Hull, G. F. Pineo, P. D. Stein, A. F. Mah, S. M. MacIsaac, O. E. Dahl, M. Butcher, R. F. Brant, W. A. Ghali, D. Bergqvist, et al.
Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty: A Systematic Review
Ann Intern Med, November 20, 2001; 135(10): 858 - 869.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
M T NURMOHAMED and B A C DIJKMANS
Prevention of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty: a continuing matter of debate
Ann Rheum Dis, October 1, 2001; 60(10): 905 - 907.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
R. D. Hull, G. F. Pineo, P. D. Stein, A. F. Mah, S. M. MacIsaac, O. E. Dahl, W. A. Ghali, M. S. Butcher, R. F. Brant, D. Bergqvist, et al.
Timing of Initial Administration of Low-Molecular-Weight Heparin Prophylaxis Against Deep Vein Thrombosis in Patients Following Elective Hip Arthroplasty: A Systematic Review
Arch Intern Med, September 10, 2001; 161(16): 1952 - 1960.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. Hull, G. Pineo, L. Landow, A. G.G. Turpie, A. S. Gallus, and J. A. Hoek
A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis
N. Engl. J. Med., July 26, 2001; 345(4): 291 - 292.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. E. Bajjoka, R. Hull, G. Pineo, C. Francis, D. Bergqvist, C. Fellenius, A. Mah, and R. Brant
Dalteparin vs Warfarin in Hip Arthroplasty Patients
Arch Intern Med, March 12, 2001; 161(5): 776 - 777.
[Full Text] [PDF]

Home page
 ChestHome page
W. H. Geerts, J. A. Heit, G. P. Clagett, G. F. Pineo, C. W. Colwell, F. A. Anderson Jr., and H. B. Wheeler
Prevention of Venous Thromboembolism
Chest, January 1, 2001; 119(1_suppl): 132S - 175S.
[Full Text] [PDF]

Home page
 NEJMHome page
R. H. White, S. Gettner, J. M. Newman, K. B. Trauner, and P. S. Romano
Predictors of Rehospitalization for Symptomatic Venous Thromboembolism after Total Hip Arthroplasty
N. Engl. J. Med., December 14, 2000; 343(24): 1758 - 1764.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
R. D. Hull, G. F. Pineo, C. Francis, D. Bergqvist, C. Fellenius, K. Soderberg, A. Holmqvist, M. Mant, R. Dear, B. Baylis, et al.
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin/Out-of-Hospital Placebo in Hip Arthroplasty Patients: A Double-blind, Randomized Comparison
Arch Intern Med, July 24, 2000; 160(14): 2208 - 2215.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
E. A. SALVATI, V. D. PELLEGRINI, N. E. SHARROCK, P. A. LOTKE, D. W. MURRAY, H. POTTER, and G. H. WESTRICH
Symposium - Recent Advances in Venous Thromboembolic Prophylaxis During and After Total Hip Replacement
J. Bone Joint Surg. Am., February 1, 2000; 82(2): 252 - 70.
[Full Text]

Home page
 JWatch GeneralHome page
Enoxaparin vs. Warfarin After Total Hip Arthroplasty
Journal Watch (General), August 20, 1999; 1999(820): 3 - 3.
[Full Text]